Your Top 50 most-cited badge
A badge for your website, a sentence for your CV, and a permanent page where anyone can check the rank.
The article
LBA21 KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2– breast cancer
Fátima Cardoso, Heather L. McArthur, Peter Schmid, Javier Cortés, Nadia Harbeck, Melinda L. Telli and 14 more
- Rank
- 18 of 3,639
- Percentile
- top 0.5%
- Where
- Annals of Oncology, 2023
- Citations
- 134
From the 2023 list, OpenAlex counts as of 2026-10-29.
Prefer not to be listed? The same link lets you withhold your name on every list; the article stays, your name does not. Questions: team@avidnote.com.